$Thalidomide: near complete regression of extramedullary bulk in refractory multiple myeloma$

Thalidomide: near complete regression of extramedullary bulk in refractory multiple myeloma

Bibliographic Details
Main Authors:	A Anagnostara, L Jost
Format:	Article
Language:	English
Published:	SMW supporting association (Trägerverein Swiss Medical Weekly SMW) 2001-03-01
Series:	Swiss Medical Weekly
Subjects:	multiple myeloma Thalidomide
Online Access:	https://www.smw.ch/index.php/smw/article/view/35

Similar Items

Bortezomib, thalidomide, and dexamethasone versus thalidomide and dexamethasone for response rates in multiple myeloma patients: a retrospective study
by: Juan M. Cano-Calderón, et al.
Published: (2025-01-01)

Integrated analysis of randomized controlled trials evaluating bortezomib + lenalidomide + dexamethasone or bortezomib + thalidomide + dexamethasone induction in transplant-eligible newly diagnosed multiple myeloma
by: Laura Rosiñol, et al.
Published: (2023-11-01)

REAL WORLD MULTIPLE MYELOMA REGISTRY FROM JORDAN, A DEVELOPING COUNTRY.
by: Abdalla Awidi, et al.
Published: (2022-04-01)

Immunomodulatory Compounds (Imids®) in the Treatment of Multiple Myeloma
by: Gordan Srkalovic, et al.
Published: (2009-10-01)

Matching‐adjusted indirect comparison of efficacy and safety of bortezomib, thalidomide, and dexamethasone (VTd) as per label compared with modified VTd dosing schedules in patients with newly diagnosed multiple myeloma who are transplant eligible
by: Pieter Sonneveld, et al.
Published: (2020-11-01)

Restarting Thalidomide-Dexamethasone Regimen in a Post-Abortive Female with Multiple Myeloma: Effective Clinical Response Possible
by: Suhailur Rehman, et al.
Published: (2017-07-01)

Assessing Pretransplant and Posttransplant Therapy Response in Multiple Myeloma Patients
by: Cristina Potre, et al.
Published: (2022-11-01)

QoL during KTd or KRd induction followed by K maintenance or observation in transplant noneligible patients with newly diagnosed multiple myeloma: Longitudinal and cross‐sectional analysis of the randomized AGMT 02 study
by: Heinz Ludwig, et al.
Published: (2024-06-01)

Extramedullary plasmacytoma of the orbit complicating the evolution of multiple myeloma in complete remission
by: Nader Slama, et al.
Published: (2024-01-01)

Incidence of Extramedullary Myeloma in Multiple Myeloma Patients
by: Sinan Demircioğlu, et al.
Published: (2019-07-01)

THE TREATMENT OF MULTIPLE MYELOMA PATIENTS NOT ELIGIBLE FOR ASCT
by: Paul Richardson, et al.
Published: (2010-05-01)

THE TREATMENT OF MULTIPLE MYELOMA PATIENTS NOT ELIGIBLE FOR ASCT
by: Anuj Mahindra, et al.
Published: (2010-05-01)

Thalidomide: from tragedy to promise
by: R Stolz
Published: (2003-02-01)

Isolated Non-Secretory Extramedullary Relapse of Multiple Myeloma Responded Completely to Localized Radiotherapy
by: Danny Dawd, et al.
Published: (2024-03-01)

Real-world outcomes of maintenance therapy post-autologous stem cell transplantation in newly diagnosed multiple myeloma
by: Ka-Won Kang, et al.
Published: (2025-02-01)

Extramedullary Plasmacytoma of the Maxillary Sinuses in a Patient With Multiple Myeloma
by: Caleb Boehler, et al.
Published: (2024-04-01)

Multiple myeloma with extramedullary plasmacytoma: pathogenesis and clinical case
by: M. V. Firsova, et al.
Published: (2022-11-01)

Case report: Dual-targeted BCMA and CS1 CAR-T-cell immunotherapy in recurrent and refractory extramedullary multiple myeloma
by: Xiangjun Shi, et al.
Published: (2024-07-01)

Unusual painful pelvic masses: Extramedullary hematopoiesis with extramedullary multiple myeloma
by: Jennifer Cai, et al.
Published: (2024-05-01)

Thalidomide as Treatment of Lip’s Pyogenic Granuloma
by: Lai L, et al.
Published: (2025-03-01)

Thalidomide failed to inhibit angiogenesis and fibrosis in hepatic schistosomiasis of the mouse
by: Camila Bião Lima, et al.
Published: (2007-11-01)

Selinexor combined with bortezomib, lenalidomide, and dexamethasone for the treatment of newly diagnosed multiple myeloma with extramedullary disease
by: Junjing Yin, et al.
Published: (2024-11-01)

Extramedullary Pulmonary Manifestations of Relapsed/Refractory Multiple Myeloma: A Case Series and Brief Review of the Literature
by: Sagar Kumar, et al.
Published: (2024-09-01)

Preclinical Evaluation of a Novel Series of Polyfluorinated Thalidomide Analogs in Drug-Resistant Multiple Myeloma
by: Blaire E. Barton, et al.
Published: (2024-06-01)

Therapeutic failure with thalidomide in patients with recurrent intestinal bleeding due to angiodysplasias
by: María del Carmen Izquierdo Navarro, et al.
Published: (2016-05-01)

Cardiovascular events associated with thalidomide and prednisone in leprosy type 2 reaction
by: Melissa de Almeida Corrêa Alfredo, et al.
Published: (2024-01-01)

Monoclonal Antibodies in Relapsed-Refractory Multiple Myeloma
by: Ilaria Sorgiovanni, et al.
Published: (2025-01-01)

Combined Proteasome and Autophagy Inhibition in Relapsed/Refractory Multiple Myeloma—A Phase I Trial of Hydroxychloroquine, Carfilzomib, and Dexamethasone
by: Tobias S. Slørdahl, et al.
Published: (2025-02-01)

Relapse of multiple myeloma presenting as extramedullary plasmacytoma surrounding the aorta: A rare case report
by: Omer Ekinci, et al.
Published: (2020-12-01)

“Fast but not so furious”: A condensed step‐up dosing schedule of teclistamab for relapsed/refractory multiple myeloma
by: Kevin C. Graf, et al.
Published: (2024-08-01)

Efficiency of pomalidomide therapy in patients with multiple myeloma refractory to lenalidomide
by: I. G. Rekhtina, et al.
Published: (2019-04-01)

Efficacy of Lenalidomide plus Low-Dose Dexamethasone in Thai Patients with Relapsed and/or Refractory Multiple Myeloma
by: Chutima Kunacheewa, et al.
Published: (2021-04-01)

Off-label use of thalidomide for the treatment of a bleeding cutaneous metastasis
by: Federico Silvestri, et al.
Published: (2015-10-01)

Molecular Mechanisms of the Teratogenic Effects of Thalidomide
by: Tomoko Asatsuma-Okumura, et al.
Published: (2020-05-01)

Clinical efficacy of thalidomide for various genotypes of beta thalassemia
by: Wei-jia Yang, et al.
Published: (2024-07-01)

Pulmoner extramedullary hematopoiesis mimicking plasmacytoma in a patient with multiple myeloma candidate for autoHSCT
by: Serdar Sivgin
Published: (2014-08-01)

Efficacy of Bendamustine, Pomalidomide, and Dexamethasone (BPD) Regimen in Relapsed/Refractory Extramedullary Myeloma: A Retrospective Single-Centre Study, Real-Life Experience
by: İbrahim Halil Açar, et al.
Published: (2023-08-01)

Is There a Role for Daratumumab Retreatment in Patients with Relapsed/Refractory Multiple Myeloma?
by: Davor Galusic, et al.
Published: (2025-01-01)

Case report: An uncommon presentation of extramedullary plasmacytoma without a concurrent diagnosis of multiple myeloma
by: Katarzyna Stawarz, et al.
Published: (2024-06-01)

Survival trends and prognostic factors of patients with newly diagnosed multiple myeloma accompanied with extramedullary disease
by: Jing Wang, et al.
Published: (2023-12-01)